Epirus Biopharmaceuticals, Inc. and Zalicus Inc., announced today that they have entered into a definitive agreement under which Epirus will merge with a wholly-owned subsidiary of Zalicus in an all-stock transaction.
The FDA has approved a new injectable drug from GlaxoSmithKline plc for adults with Type 2 diabetes. The agency cleared the company's drug, Tanzeum, to help patients control their blood sugar levels, in combination with diet and exercise.
Fluid Imaging Technologies Announces Call for Submissions for First Annual Life Sciences & Materials Research GrantApril 15, 2014 4:25 pm | by Fluid Imaging Technologies Inc. | News | Comments
Laboratory instrumentation manufacturer Fluid Imaging Technologies is pleased to announce the call for submissions for its Life Sciences & Materials Research Grant.
The new PURAIR 5 Ductless Fume Hoods feature a high level of operator protection where routine histology, powder weighing and sampling prep work is being carried out.
A high-tech screening tool for cervical cancer is facing pushback from more than a dozen U.S. patient groups, who warn that the genetic test could displace a simpler, cheaper and more established mainstay of women's health: the Pap smear.
February U.S. manufacturing technology orders totaled $354.40 million according to AMT - The Association For Manufacturing Technology. This total, as reported by companies participating in the USMTO program, was down 6.6% from January and down 6.2% when compared with the total of $377.82 million reported for February 2013. With a year-to-date total of $733.82 million, 2014 is down 0.6% compared with 2013.
PSX1001 and PSX1050, which are the first products to emerge from Prosonix's innovative and proprietary particle engineering platform, are being developed as generic versions to GlaxoSmithKline's pressurized metered dose inhalers (pMDI) Flixotide® and Flovent®, respectively.
There's heightened concern after the confirmation of more cases of the deadly Middle East Respiratory Syndrome, or MERS, in Saudi Arabia and Jordan over the weekend.
Report details the dangers of testing Ebola, which has already claimed the lives of 14 healthcare workers.
The Congressional Budget Office predicts that health insurance subsidies under the so-called "Obamacare" plan will total a little more than $1 trillion over the next 10 years, instead of almost $1.2 trillion initially estimated.
Massachusetts' ban of a powerful new painkiller, Zohydro, remains in effect for now. U.S. District Court Judge Rya Zobel heard more arguments Monday in a lawsuit that claims the state is overstepping its authority in restricting drug use within Massachusetts in violation of the U.S. Constitution.
Merck has announced that FDA has approved GRASTEK ® (Timothy Grass Pollen Allergen Extract) Tablet for Sublingual Use [2800 Bioequivalent Allergy Units (BAU)]. GRASTEK is an allergen extract indicated as immunotherapy for the treatment of grass pollen-induced allergic rhinitis with or without conjunctivitis.
DesignMedix, Inc., a biotech startup with ties to Portland State University, received a grant for almost $3 million from the National Institutes of Health to continue development and manufacture of a new anti-malarial drug.
Johnson & Johnson today announced sales of $18.1 billion for the first quarter of 2014, an increase of 3.5% as compared to the first quarter of 2013. Operational results increased 5.3% and the negative impact of currency was 1.8%. Domestic sales increased 2.2%. International sales increased 4.5%, reflecting operational growth of 7.9% and a negative currency impact of 3.4%.
Tied to an unpopular president and his signature health care law, Democrats in the nation's largest swing state see medical marijuana as a potential antidote to political malaise in this year's midterm elections.